Title : Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy.

Pub. Date : 2014 Mar

PMID : 24155212






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The low expression of RRM1 and RRM2 significantly increased the platinum-based chemotherapy response (For RRM1: odds ratio (OR) = 2.09, 95% confidence interval (CI) = 1.38-3.18; For RRM2: OR = 1.64, 95% CI = 1.09-2.48). Platinum ribonucleotide reductase catalytic subunit M1 Homo sapiens
2 The low expression of RRM1 and RRM2 significantly increased the platinum-based chemotherapy response (For RRM1: odds ratio (OR) = 2.09, 95% confidence interval (CI) = 1.38-3.18; For RRM2: OR = 1.64, 95% CI = 1.09-2.48). Platinum ribonucleotide reductase catalytic subunit M1 Homo sapiens
3 In conclusion, low expression of RRM1 and RRM2 could be used to predict the treatment response to platinum-based chemotherapy and survival in NSCLC. Platinum ribonucleotide reductase catalytic subunit M1 Homo sapiens